News

BADBIR Annual Update 2024

BADBIR Annual Update 2024

by | Nov 28, 2024 | Clinician Newsletters, Newsletters

Welcome to the 2024 BADBIR Update. Led by the British Association of Dermatologists and co-ordinated at the University of Manchester, since 2007 BADBIR has grown to be a leading source of real-world data for researching psoriasis therapies.While we prepare this...

Taltz (ixekizumab) recruitment will end on 31st July 2024

by | Jul 22, 2024 | News

Please be aware that BADBIR cannot accept any new registrations at baseline for patients starting Taltz after 31st July. Participants must have started treatment and provided consent before 1st August to be accepted. If participants signed consent and commenced Taltz...

Uptake of tumour necrosis factor-alpha inhibitor biosimilars for psoriasis: a drug utilization study from the British Association of Dermatologists Biologic and Immunomodulators Register (BADBIR)

Uptake of tumour necrosis factor-alpha inhibitor biosimilars for psoriasis: a drug utilization study from the British Association of Dermatologists Biologic and Immunomodulators Register (BADBIR)

by | Jun 24, 2024 | Publications

Duc Binh Phan, Anthony P Bewley, Catherine H Smith, Teena Mackenzie, Christopher E M Griffiths, Mark Lunt, Richard B Warren, Zenas Z N Yiu British Journal of Dermatology, Volume 189, Issue 1, July 2023, Pages 62–70, https://doi.org/10.1093/bjd/ljad107Published: 05...

Centre of the month: June 2024

Centre of the month: June 2024

by | Jun 21, 2024 | Centre Recognition Award

Hull University Teaching Hospitals NHS Trust was selected for their hard work resolving queries and getting patients up-to-date. A message from Hull: BADBIR has shown how effective team working helps clinicians and patients provide safe and quality care for our...

Centre of the month: February 2024

Centre of the month: February 2024

by | Feb 21, 2024 | Centre Recognition Award

Ashford and St Peter's NHS Foundation Trust was selected for their hard work keeping on top of outstanding follow-ups. A message from Ashford and St Peter's: We are really proud to have been selected as the BADBIR centre of the month. Our team has worked really hard...

Recruitment open to Spevigo (spesolimab)

by | Feb 1, 2024 | News

We are now accepting patients on Spevigo (spesolimab). Spevigo is indicated for the treatment of flares in adult patients with generalised pustular psoriasis (GPP). BADBIR can accept registrations for patients with a GPP diagnosis.Please see the eligibility page for...